P3354
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to TrastuzumabSafety Study of BEZ235 With Everolimus in Subjects With Advanced Solid TumorsBEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerSafety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
P4844
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsAntitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.PAK1 mediates resistance to PI3K inhibition in lymphomas.The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.Studies of NVP-BEZ235 in melanoma.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivityThe synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
BEZ235
@sh
BEZ235
@sr
dactolisib
@en
داکتولیسیب
@fa
type
label
BEZ235
@sh
BEZ235
@sr
dactolisib
@en
داکتولیسیب
@fa
altLabel
BEZ 235
@en
BEZ-235
@en
BEZ235
@en
Dactolisib
@en
NVP BEZ235
@en
NVP-BEZ 235
@en
NVP-BEZ235
@en
NVPBEZ235
@en
prefLabel
BEZ235
@sh
BEZ235
@sr
dactolisib
@en
داکتولیسیب
@fa
P129
P486
P592
P661
P662
P683
P117
P129
P1579
P2067
P2275
dactolisib
@en
P231
915019-65-7
P233
CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
P234
1S/C30H23N5O/c1-30(2,18-31)22- ...... (28)34(3)29(35)36/h4-17H,1-3H3
P235
JOGKUKXHTYWRGZ-UHFFFAOYSA-N
P274
P2840
P2868
P3117
DTXSID10238599